An Epstein-Barr virus-associated superantigen by unknown
An Epstein-BarrVirus-associated  Superantigen 
By Natalie Sutkowski,* Tessa Palkama,* Cristina Ciurli,~ 
Rafick-Pierre Sekaly,~ David A.Thorley-Lawson,* and Brigitte T. Huber* 
From the *Department of Pathology, Tufts University School of Medicine, Boston, 
Massachusetts 0211 I; and the C  Laboratory of Immunology, Institute for Clinical 
Research of Montreal, Montreal, PQ, Canada, H2 W  IR7 
Summary 
More  than  90%  of adults  are  latently infected  with  Epstein-Barr virus  (EBV),  the  causative 
agent of infectious mononucleosis, a self-limiting lymphoproliferative disease characterized by 
extensive T  cell activation. Reactivation of this herpesvirus during immunosuppression is often 
associated with oncogenesis. These considerations led us to analyze the early events that occur 
after  exposure  of the  immune  system  to  EBV.  Strong  major  histocompatibility  complex 
(MHC) class lI-dependent, but not MHC-restricted, T  cell proliferation was observed in vitro 
in response to autologous,  lytically infected EBV-transformed B  cells.  By measuring the  ap- 
pearance of the early activation marker CD69 on individual T  cell V[3 subsets, we could dem- 
onstrate selective activation of human VI313 + T  cells.  This was confirmed with murine T  cell 
hybridomas expressing various human BV genes. While EBV- Burkitt's lymphoma cells were 
nonstimulatory, they induced V]3-restricted T  cell activation after EBV infection. EBV specific 
activation was also demonstrated in cord blood cells, excluding a recall-antigen response. Thus, 
all of the characteristics of a superantigen-stimulated response are seen, indicating that induc- 
tion of the  EBV lyric cycle is associated with the  expression of a superantigen  in B  cells.  A 
model is presented proposing a role for the superantigen in infection, latency, and oncogenesis. 
E  BV has a strong tropism for B lymphocytes and has the 
capacity  to  activate  them  to  proliferate  continuously 
(reviewed in 1, 2). Exposure to EBV during childhood re- 
suits  in no symptoms or only limited symptoms. Infection 
during adolescence or early adulthood,  however,  can give 
rise  to  infectious mononucleosis  (IM) l  in ,-~  of cases. 
IM is a self-limiting lymphoproliferative disease character- 
ized by virus shedding into the saliva,  growth of infected B 
cells,  and a  massive expansion of nonspecific T  cells.  Ini- 
tially, both  CD4 +  and  CD8 +  T  cells  are  activated;  how- 
ever,  later  on,  the  response  comprises  mainly  atypical 
CD8 + lymphoblastoid cells. Disease regression occurs grad- 
ually, manifested by a decrease in virus shedding as well as 
in the number of infected B cells. Presumably, this is medi- 
ated by virus-specific CTL (3). 
EBV  is  a  highly successful virus,  which  has  evolved to 
inhabit and manipulate the immune system to its own ad- 
vantage.  The  infection  of antigen-presenting B  cells,  fol- 
lowed by a rapid activation of nonimmune T  cells,  led us 
to speculate that an EBV-associated superantigen might be 
influencing the immune response during the establishment 
of persistent infection. 
1Abbreviations used in  this paper: CBMC, cord blood mononuclear cells; 
IM, infectious mononucleosis; LCL, lymphoblastoid cell line; MMTV, 
murine mammary  tumor virus; SEB, Staphylococcus enterotoxin B. 
Superantigens  are  a  class  of pathogen-derived  proteins 
that elicit a powerful T  cell response, activating whole fam- 
ilies oft  cells with identical or related TCR V13 chains (re- 
viewed in 4).  Superantigens form a bridge between MHC 
class II molecules on APC and a region on the TCI/, V[3 
chain outside of the unique  antigen-binding domain. This 
bridging  transduces  a  signal  to  the  T  cell  as  well  as  the 
APC, resulting in activation of both. The hallmarks ofa su- 
perantigen-induced T  cell response are (a) a vigorous acti- 
vation of primary T  cells;  (b) an MHC class II-dependent, 
but not MHC-restricted, recognition; and (c) a TCk  V[3- 
restricted response.  Exposure  to  superantigens  in vivo re- 
suits  in skewing of the T  cell repertoire, manifested either 
by amplification of particular T  cell V[3 families, or deletion 
and/or anergy of specific subsets. A virally encoded super- 
antigen could have irreversible, indirect effects on the hu- 
man immune system by altering the response to pathogens, 
leading  to  disease  or  autoimmunity.  An  example is  pro- 
vided by the recent demonstration that the murine mam- 
mary  tumor virus  (MMTV)  superantigen,  Mls-1,  predis- 
poses  mice  to  polyoma  virus  associated  oncogenesis  by 
deleting  the  cytotoxic  T  cells  that  control  polyoma virus 
infection (5). 
Superantigens  are  evolutionarily  conserved  in  certain 
pathogens,  and it is presumed that they confer a selective 
advantage  for the  microbe.  It has been well  documented 
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typic viral superantigen, Mls, is essential for transmission of 
infectious MMTV  (6-8).  Therefore,  we  set  out to  deter- 
mine whether superantigen stimulation of the human im- 
mune system could likewise play a role in establishing per- 
sistent EBV infection and disease. 
Materials and Methods 
Proliferation Assays.  Peripheral  blood  B  cells from  healthy 
adult volunteers were transformed  to create  lymphoblastoid cell 
lines (LCL), using viral supernatant from B95-8 cells, which pro- 
duce a common laboratory strain  of EBV  (9,  10), or IM-1, an 
EBV strata isolated from an IM patient (a gift from M.A. Epstein, 
University of Oxford, England). LCL were stimulated with PMA 
(10  ng/ml) for  24  h  to  induce the  lytic  cycle,  and were  then 
treated  with mitomycin C  (100 b~g/ml) for 1 h to arrest cellular 
division.  After extensive washing with PBS, LCL were added  to 
freshly isolated  autologous PBMC  or allogeneic  umbilical cord 
blood mononuclear cells (CBMC). PBMC and CBMC were iso- 
lated by density gradient separation  on Ficoll-Paque Plus  (Phar- 
macia,  Uppsala,  Sweden).  All  cells were  cultured in complete 
RPMI media (GIBCO BRL, Gaithersburg,  MD), supplemented 
with 10% FCS (Intergen, Purchase,  NY), at 37~  with 5% CO2. 
Each  assay was  carried  out in quadruplicate wells  of a 96-well 
plate with 105 responders/well,  using stimulator to responder ratios 
of 1:3  and  1:10. Stinmlation was  compared  to  treatment with 
PHA (2 I.tg/ml). After an incubation period of 48 h, the cells were 
pulsed  with  [3H]thymidine  (1  I.LCi/well) and harvested  8-12 h 
later to assess DNA synthesis as a measure of cellular proliferation. 
Similar assays were performed using as APC two EBV- Bur- 
kitt's lymphoma tumors, BL-2 and BL-41  (11), both before  and 
subsequent to productive infection with B95-8 supernatant. APC 
were treated with PMA and mitomycin C and plated with alloge- 
neic PBMC or CBMC at APC/responder ratios of 1:1, 1:3, or 1:10. 
MHC Class II-blocking Experiments.  Proliferation  assays were 
performed as described  above,  with the following modifications: 
before the addition of responder cells, in some of the wells, LCL 
were preincubated for 1 h with Dl-12 (80 btg/ml),  an mAb that 
recognizes  all HLA DR molecules  (12), or the same concentra- 
tion of an isotypic control mAb 116-13.1,  anti-lyt-2. The n~Ab 
remained in the cultures for the entire 72 h. Each assay was set up 
using autologous PBMC  from adult donors as  responders,  and 
with a stimulator/responder ratio  of 1:10. As a control, D1-12 
(80 ~g/ml) was also added to PHA-treated cells. 
CD69 Staining qf hldividual V~8 Subsets.  Freshly  isolated  au- 
tologous  PBMC  were  stimulated for  4  h  with  PMA-induced 
B95-8 LCL or IM-1 LCL in one well of a six-well plate using I0  v 
PBMC and 1.25 X 1(35 stinmlators (stimulator/responder  =  1:80). 
As a control, PBMC were likewise  stimulated  either with PHA 
or Staphylococcus enterotoxin B  (SEB; Sigma  Immunochemicals, 
St. Louis, MO) (1  txg/ml) for 4 h. Stimulated cells were then im- 
mediately  double stained  with PE-conjugated anti-CD69 mAb, 
and a panel ofanti-V[~ mAb that were either directly FITC con- 
jugated, or if unconjugated, FITC-conjugated rabbit anti-mouse 
IgG (Zymed Laboratories,  South San Francisco, CA) was used as 
a second step reagent.  Cells were analyzed on a FACScan  |  (Bec- 
ton Dickinson &  Co.,  Mountain View,  CA)  to  determine the 
percentage  of each  V[3  subset that became CD69 +.  The results 
were calculated for each staining according to the following for- 
nmla:  number  of  double-positive  cells (V]3  +,  CD69+)/total 
number ofVI3 + cells in each subfanfily. This readout is indepen- 
dent of variations  in size of individual V]3  compartments, since 
only the  change in CD69  expression  is  recorded.  Background 
levels of CD69  staining were "'3% on unstimulated cells from 
each donor. 
Antibodies.  D1-12,  anti-HLA DR  (12); PE-CD69  (Becton 
Dickinson);  FITC-V[32,  14-23  (ImmunoTech Corp.,  Boston, 
MA); VIB3a, 8F10; V135b, Wll2; VI38a, 16G8  (T Cell Diagnos- 
tics,  Woburn,  MA);  V[35a, 42/1C1  (13); VI35c, LC4  (14); 
V[36.7a, OT145 (15); VI38b, MX6 (16); VI312, $511 (17); V[313, 
H131  (18); 145-2Cll, antimurine CD3 (19); OKT3, anti-human 
CD3,  116-13.1,  antinmrine CD8 (American  Type Culture Col- 
lection, Bethesda,  MD).  The VI33-13 mAbs were supplied  as a 
generous gift from Walter Tian ofT Cell Diagnostics and Chuck 
Ritterhouse of T  Cell Sciences  (Cambridge,  MA)  to  the TCR. 
mAb Workshop  participants  (Human TCR  Monoclonal Anti- 
body Workshop, July 26, 1995, San Francisco, CA). 
Stimulation qf Murine T Cell Hybridomas Expressing Human  Vl813 
Genes.  The  murine  T  cell  hybridomas  hV[313.1, hV[313.2, 
hV[313.6,  hV[32, hV[33, and hV]39 were  provided by Philippa 
Marrack  (National Jewish Center for Immunology and Respira- 
tory Medicine, Univ. of Colorado Health  Sciences Center, Den- 
ver,  CO).  The  derivation  of  the  hV]313 lines,  hV~13.1-1, 
hVI313.2-1,  and hV1313.3-1, has been previously described  (18, 
20); the hV[39 T  cell hybrid DS3-A was constructed in a similar 
manner. They express the particular human VI3 gene in the con- 
text of nmrine Vcl and CD3 chains.  It should be noted that the 
hV]313.3-1 hybridoma actually expresses VI313.6, according to a 
recent revision of the V]313 family nomenclature (21). The hV[32 
hybrid, TAL 8.1.9, has been previously described (22). The hV]33 
hybrid,  58cx [3-/HAI-7cl/[3, expresses human Veil.2  and V]33 
fused to a nmrine constant region. The hV]38 and hV[317.1 hy- 
brids,  YL138#24 and YL[317.1#15,  were  constructed by Victor 
Dumas in the Sekaly lab  (unpublished data), by transfecting  the 
murine T hybrid, YL{3- (a gift from Osami Kanagawa, Washing- 
ton University School  of Medicine, St.  Louis,  MO),  with  the 
R.SV.5neo  vector  (23) containing the  particular  human genes. 
These express murine Vot and C1)3 chains. 
T  cell  hybridomas were  cultured  for  24-36  h  with  PMA- 
treated  B95-8 or IM-I LCL,  or Burkitt's lymphoma cells, using 
2 X 104 responders/well in quadruplicate  wells of a 96-well plate, 
and stimulator/responder ratios of 1:1  or 1:3. As control, T  cell 
hybridomas were stimulated  by cross-linking the TCP, on anti- 
CD3-coated wells  (145-2Cll ascites, diluted 1:3,000).  Cell  ly- 
sates were prepared by freezing the plates for at least 12 h, and IL-2 
production was  monitored in a  bioassay using HT-2  indicator 
cells (24). 
Results 
Peripheral  Blood  T  Cells  Proliferate in  Response  to Autolo- 
gous,  Lyrically It~ected EBV-transformed B  Cells.  To  inves- 
tigate whether  a  vitally associated  superantigen influences 
the establishment of persistent EBV infection, a classical  T 
cell proliferation assay was performed. In this assay, lytically 
infected, EBV-transformed B  LCL were used as APC, and 
autologous PBMC from healthy adult donors served as re- 
sponders. This constituted an attempt to reproduce in vitro 
some of the initial events that occur during IM, leading to 
the massive T  cell activation. It has not been possible to de- 
cipher these primary steps in vivo using IM patient blood 
samples,  most likely because noticeable clinical symptonls 
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lytically infected EBV-transformed B cells, and to an allogeneic EBV  +, 
but not EBV-, Burkitt's lymphoma. B95-8 or IM-1 LCL, EBV- BL-2 
cells, and B95-8-infected BL-2 cells were stimulated with PMA for 24 h 
to induce lytic viral replication and treated with mitomycin C for use as 
APC. Freshly isolated PBMC from donor 1 (A) and donor 2 (/3) were 
then added to autologous LCL or allogeneic BL-2 cells. Each assay was 
carried out using stimulator to responder ratios of 1:3 and 1:10. Stimula- 
tion with PHA was used as a positive control. 48 h proliferation was as- 
sessed by [3H]thymidine incorporation as a measure of DNA synthesis. 
Results were assessed in quadruplicate, and are expressed as the average 
cpm/well with the SD. 
often do not appear until after the disease has progressed to 
the lymphoproliferative stage. At that point, there is signifi- 
cant  bystander  T  cell  activation,  resulting  from  cytokine 
production  and  the  generally  activated  immune  status, 
which can obscure EBV-specific T  cell activation. 
LCL  were  established  in  vitro  by  infection  of B  cells 
with two different strains of EBV: B95-8, a common labo- 
ratory strain,  and IM-1, a viral isolate derived from the pe- 
ripheral  blood  of an  IM  patient.  Since  EBV  is  generally 
maintained in a latent form in LCL, we stimulated the cell 
lines for 24 h  with the phorbol ester PMA, which induces 
the EBV lytic cycle and upregulates the production of viral 
proteins  (25). Figs.  1, A  and B, depict representative  results 
obtained  with  PBMC  from  two  healthy  unrelated  adult 
donors.  In  both  cases,  48  h  proliferation,  as  assessed  by 
[3H]thymidine  incorporation,  was  demonstrated  at  levels 
comparable  to the  mitogen PHA.  Maximum  proliferation 
occurred at 72 h, although the absolute levels were not sig- 
nificantly  higher  (data  not  shown).  To  demonstrate  that 
EBV  is  responsible  for the  strong proliferation,  an  EBV- 
Burkitt's lymphoma line, BL-2, was PMA treated for use as 
APC. Although allogeneic, these cells were found to be non- 
sfimulatory or very weakly stimulatory at 48 h under identi- 
cal conditions. Upon infection of the BL-2 cells with B95-8 
EBV, strong proliferation was observed (Fig. 1, A  and B). 
The Early Activation Marker CD69 Is Preferentially Expressed 
on  V~813 T  Cells after a 4-h  Stimulation  with Autologous  B95-8 
LCL.  The main characteristic  of a superantigen is that it 
elicits  a TCR  Vl3-restricted  response,  resulting  in a selec- 
tive alteration  of the T  cell repertoire by either amplifying 
or deleting T  cell clones that express the specific VI3 genes. 
If indeed the stimulation with autologous LCL is caused by 
the presence of a superantigen,  we would expect to selec- 
tively activate T  cells of  a particular TCt< VJ3 phenotype. To 
test this,  we developed a novel means of defining Vl3-specific 
T  cell  activation;  namely,  we  analyzed  the  appearance  of 
the  early  activation  marker  CD69  (26,  27)  on  individual 
T  cell V[3  subsets  4  h  after stimulation.  Cytokines,  which 
are potent activators of bystander T  cells,  are produced be- 
tween  5-6 h  after stimulation;  thus,  we deliberately  chose 
an earlier time point to minimize the induction of nonspe- 
cific T  cell proliferation.  Moreover, the absence of  prolifer- 
ation at this early time point guarantees detection ofa poly- 
clonal  response,  excluding  the  readout  of an  oligoclonal 
expansion.  This  obviates the need for sequencing the VDJ 
region of numerous clones to establish polyclonality. 
PBMC  from  the  same  two  donors  depicted  in  Fig.  1 
were  stimulated  for  4  h  with  autologous  B95-8  LCL  or 
with PHA, The cells  were then double stained with a PE- 
conjugated  anti-CD69  mAb and a  panel  of FITC-labeled 
anti-V[3 mAbs. The stimulated cells  were analyzed by flow 
cytometry to  assess  the percentage  of each VI3  subset  that 
expressed  CD69.  As  can be  seen  in  Fig.  2  A,  stimulation 
with  LCL  led  in  both  donors  to  a  significant  increase  in 
CD69 +  cells  in  the  VJ313  T  cell  subset.  As  expected,  the 
percentage of CD69 + cells  after stimulation with the mito- 
gen PHA did not vary significantly between the VI3 subsets 
and was not significantly different from the overall percent- 
age ofCD69 + cells  in unfractionated PBMC. These results 
suggest that EBV induces in B cells the expression of a pro- 
tein that is preferentially recognized by polyclonal V1313 T 
cells,  implicating the presence of a superantigen.  Similar re- 
sults  were obtained after stimulation with autologous IM-1 
LCL, and with a third donor using autologous LCL as well 
(data  not  shown).  After  longer  stimulation  with  PHA  or 
LCL (>4 h),  CD69 was expressed on a greater percentage 
of T  cells  (data not shown), probably because of activation 
of bystander  T  cells  by  the  ensuing  production  of cyto- 
kines. 
To ensure that the appearance of CD69 on particular V[3 
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Figure  2.  The  early activation 
marker CD69 is preferentially ex- 
pressed on V~13 T cells after a 4-h 
stimulation with autologous B95-8 
LCL, and  on  VI~12 T  cells alter 
SEB stinmlation.  Autologous PMA- 
induced B95-8 LCL were cultured 
for 4 h with freshly isolated PBMC 
from two  donors, as described in 
Materials and  Methods. As  con- 
trols,  PBMC  from each donor 
were  simultaneously stimulated 
with  PHA  (A). Stimulated  cells 
were  immediately double  stained 
with  PE-conjugated  anti-C1)69 
mAb and a panel of FITC-conju- 
gated  anti-VI3 mAb. Analysis by 
flow  cytometry  determined  the 
percentage of each VI3 subset that 
became  CD69 +.  l,  B95-8; [~, 
PHA.  (B)  In  a  separate experi- 
ment, PBMC from the same two 
donors were stimulated with SEB 
for 4 h and stained as described in 
A;  again, stinmlation  was  com- 
pared to PHA. The graphs depict 
the percentage of cells froln each 
V~ family that were (;1369  + after 
stinmlation  with  SEB  (1)  con> 
pared to PHA ([]). 
subsets is truly indicative of superantigen activity, we ana- 
lyzed  the  well-established superantigen  response  to  SEB. 
The results obtained with PBMC  of the same two  donors 
are summarized in Fig. 2 B. The percentage ofCD69 + cells 
after  SEB  stimulation  was  significantly  increased  in  the 
VJ312,  VJ317,  and VJ320  subsets, consistent with published 
reports  using  conventional  methods  of V[3  analyses  (28). 
The level of CD69  was highest on V~312 + cells, the subset 
shown to be deleted in an in vivo study after immunization 
with  SEB  (29).  On  the  other hand,  the  V~13  subset was 
not  significantly  elevated  for  CD69  staining  after  SEB 
treatment,  indicating that  the  increased V[313  stinmlation 
in Fig. 2 A  was specific for EBV LCL. Thus,  our assay sys- 
tem  is sensitive for  detection of V{3-specific superantigen 
sfnmlation. It should be noted, however, that after 4  h  in- 
cubation with SEB,  CD69  expression was not significantly 
increased in the V~3a  subset,  despite the reported expan- 
sion of VJ33  T  cells after long-term SEB  stimulation (28). 
Since our assay relies on the specificity of the VI3 mAb used 
for  the  detection  of T  cell subsets,  it is  our  opinion  that 
screening for  CD69  expression is  useful  only as  an  initial 
test for detection of V~ activation. 
Murine  T  Cell  Hybridomas Expressing  Human  V~I3.1, 
V~13.2,  and  V~13.6 Produce IL-2 in Response to B95-8 and 
IM-I LCL  The human VI313 fanny contains eight mere- 
bers, V{313.1-13.8,  comprising a large portion of the over- 
all T  cell repertoire (GenBank/EMBL/DDBJ  accession No. 
L36092).  The  anti-VJ313  mAb we  have  used,  H131,  was 
originally developed against the human BV13.1  gene prod- 
uct,  expressed in a murine T  cell hybridoma as a  chimeric 
TCR  with  the  murine  Vet  and  CD3  chains  (18).  The 
H131  mAb stains a relatively large percentage of peripheral 
blood cells from  each  donor tested  (3-4.5%).  Because  the 
BV13 family members are highly homologous, it is difficult 
to rule out mAb cross-reactivity between the subfamilies. 
To  confirm the finding that  LCL preferentially activate 
VI313 T  cells, we tested murine T  cell hybridomas express- 
ing human  VI313.1,  VJ313.2,  and  V~313.6  chains,  respec- 
tively (18, 20). In addition, T  cell hybrids expressing human 
V~2  (22),  VI33, VI38,  VJ39,  and V~17.1  were included in 
these experiments. These hybrids lack endogenous nmrine 
V~ genes, although the constant region and CD3  complex 
are of murine origin. The hV{32  and hVJ33  hybrids express 
human  Vet  as well,  while all of the  other hybrids express 
murine  Vet  chains.  As  can be  seen  in  Fig.  3  A, the  three 
VJ313 + T  cell hybrids produced IL-2 after stimulation with 
either  PMA-treated  B95-8  or  IM-l-derived  LCL,  but 
were only very weakly stimulated by latently infected LCL. 
On  the other hand,  the hVJ38  T  hybrid was unreactive to 
the LCL, regardless of PMA treatment. Fig. 3 B shows that 
974  An Epstein-Barr Virus Superantigen Figure 3.  Stimulation of murine T  cell hybridomas expressing  human VJ313.1, 13.2,  and 
13.6 in response to lyrically infected B95-8 and lM-1 LCL, and lytically infected EBV  +, but 
not  EBV-,  Burkitt's  lymphomas.  (A)  Murine  T  cell  hybrido,nas  expressing  hVI313.1, 
hV[313.2, hV[313.6, or hV[38 were cultured for 24-36 h with uninduced and PMA-treated 
B95-8 or IM-1  LCL.  As a positive control, T  cell hybrids were stimulated by TCR cross- 
linkage.  Cell lysates were monitored for IL-2 production by assaying HT-2 cell growth by 
[3H]thymidine  incorporation. Results were assessed in quadruplicate,  and are  expressed  as 
the average cpm/well with the SD. HT-2 cell dose response to rlL-2 is depicted on the right 
vertical  axis. [],  IM-1, no PMA; m,  IM-t  +  PMA;  D,  B95-8, no PMA;  t~, B95-8  + 
PMA; [], anti-CD3. (B) A full panel of nmrine T  cell hybrids expressing human BV genes 
were stimulated  with PMA-treated B95-8 and IM-1 LCL. The results are depicted as the per- 
centage of maximal IL-2 production, based on TCR cross-linkage,  n, IM-1; F~, B95-8. (C) 
The hV[313 T  cell  hybrids and the hVJ38 hybrid were stimulated with EBV  BL-2  and 
BL41  cells, as well as B95-8-infected BL-2 and BL-41  cells. All APC were PMA treated. 
The results are depicted as the percentage of maximal IL-2 production, based on TCR cross- 
linkage, m, BL-2, no EBV; k~, BL-2 +  B95-8;  D, BL-4I, no EBV; [], BL-41 +  B95-8. 
none of the other T  cell hybrids expressing different human 
BV genes were  stimulated by PMA  treated IM-1  or B95-8 
LCL.  The  results are  presented  as the  percentage  of maxi- 
mal  IL-2  production  based  on  anti-CD3  cross-linking, 
since the overall level of response varied between  the vari- 
ous  T  cell hybrids,  reflecting fluctuations  in  the  CD3  sur- 
face  expression.  Fig.  3  C  demonstrates that EBV is respon- 
sible  for stimulation  of the  V[313  T  hybrids.  In  this  assay, 
the VI313 hybrids produced  IL-2 in response to two  differ- 
ent  PMA  treated  EBV-  Burkitt's  lymphoma  lines,  BL-2 
and BL-41,  only after infection of the cells with B95-8  su- 
pernatant.  Again,  the  V~8  hybrid  was  unreactive.  These 
experiments  also  indicate  that  the  T  cell  response  is  not 
MHC  restricted,  since  a  similar pattern  of stimulation was 
obtained  with  PMA-induced  LCL  and  B95-8 +  BL  lines, 
despite having different HLA  haplotypes. 
Proliferation  to Antologous  EBV LCL  is MHC  Class II De- 
pendent,  but Not Restricted.  Presentation  of all known  su- 
perantigens to T  cells is dependent  on expression of MHC 
class  II  molecules.  To  determine  whether  the  T  cell  re- 
sponse  against EBV-transformed  LCL  requires  MHC  class 
II, we performed  the proliferation assays in the presence of 
the  mAb  D1-12,  which  recognizes  a  nonpolymorphic  re- 
gion on all HLA  DR  molecules.  As  can be seen in Fig.  4, 
preincubation  of  PMA-stimulated  B95-8  or  IM-1  LCL 
with  D1-12  mAb  blocked  the  induction  of autologous  T 
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Figure 4.  The anti-HLA DR mAb Dl-12 blocks the 48-h proliferation 
of PBMC to autologous,  lytically infected EBV LCL.  Proliferation assay 
was performed as in Fig. 1; however, in some of the wells, LCL were pre- 
incubated with the mAb D1-12  or an isotypic  control mAb  116-13.1, 
which remained in the cultures  throughout the assay. Autologous B95-8 
or IM-1 LCL were used as APC at a stimulator/responder ratio of 1:10. 
D1-12 added to PHA-treated cells did not affect stimulation. sary for optimal stimulation,  we have surmised that the ac- 
tivation  is  most likely  caused by an  EBV lytic  gene.  LCL 
are  easily  induced  into  the  lytic  cycle with  phorbol  ester 
(2).  Even  in  uninduced  LCL,  a  small  number  of cells  is 
present which spontaneously undergo lytic cycle viral repli- 
cation.  This number is significantly reduced in EBV + Bur- 
kitt's lymphoma lines (2).  Spontaneous lyric cycle gene ex- 
pression, in combination with the alloresponse, could account 
for  the  weak  stimulation  induced  by  non-PMA-treated 
LCL of the CBMC in Fig. 5, as well as of the T  cell hybrids 
in Fig. 3 A. 
Figure 5.  CBMC proliferate in response to lytically infected B95-8 and 
IM-1 LCL, and lytically infected EBV  +, but not EBV  , Burkitt's lym- 
phomas. Fresh CBMC were stimulated with allogeneic, uninduced, and 
PMA-treated B95-8 and IM-1 LCL at stimulator/responder ratios of 1:3 
and  1:10. CBMC  were also stinmlated with allogeneic, PMA-treated 
EBV  and B95-8-infected BL-2 and BL-41 cells at stinmlator/responder 
ratios of 1:1 and 1:3. The proliferation assay was performed as described 
in Fig. 1. 
cell  proliferation,  while  mitogen-induced  stimulation  was 
unaffected.  Preincubation  with  an  isotypic  control  anti- 
body, 116-13.1, did not block 48-h T  cell proliferation. 
T  Cell  Proliferation  to  EBV-transformed  B  Cells  Is  Not 
Caused by a Memory Response.  Since  the  vast  majority  of 
adults  are  EBV +,  the  massive  proliferation  induced  by 
EBV-transformed LCL could be caused by a recall antigen 
response.  To  test  this  possibility,  we  used  CBMC  as  re- 
sponders in this assay because newborns are EBV- and can- 
not have memory T  cells.  As can be seen in Fig. 5, CBMC 
vigorously proliferated at 48 h to allogeneic B95-8 and IM-1 
LCL after PMA induction. Weak stimulation was observed 
in response  to  uninduced  LCL.  While  the  magnitude  and 
the early kinetics of the response pointed to the action of a 
superantigen  rather than  an alloresponse,  the Burkitt  lym- 
phoma  lines  actually  confirmed  that  the  stimulation  was 
caused by EBV.  Strong proliferation was detected  only af- 
ter  PMA  treatment  of B95-8-infected  BL-2  and  BL-41 
cells.  PMA  treated  EBV-  BL  cells  were  weakly  stimula- 
tory, as would be expected from the alloresponse,  which is 
not optimal at 48 h. 
It should be mentioned that the LCL in all of our assays 
induce higher levels of T  cell stimulation than do the B95- 
8-infected  Burkitt's  lymphoma  lines.  In  Fig.  5,  although 
the  proliferation levels induced by all  of the EBV  + PMA- 
treated cells are comparable, the stimulator/responder ratios 
are  1:3 and  1:10 for the LCL, but  1:1  and  1:3 for the Bur- 
kitt's  lymphomas.  The  difference  in  stimulation  could be 
caused by several factors. LCL express higher levels than do 
most  Burkitt's  lymphoma lines  of different  cellular  adhe- 
sion  molecules,  such  as  CD23,  which possibly  enhance  T 
cell activation.  In addition,  since PMA treatment is neces- 
Discussion 
Taken  together,  the  results  presented  here  demonstrate 
the expression  of a superantigen  in EBV-transformed LCL 
and  EBV  +  Burkitt's  lymphomas  that  have  been  induced 
into the lytic cycle. The early activation of a large propor- 
tion  of nonimmune  T  cells,  combined  with  the  fact  that 
the stimulation is  HLA-DR dependent,  but not restricted, 
and the specific activation ofV[313 T  cells,  all support this 
conclusion.  Furthermore,  the  response  of the  CBMC  to 
EBV  +,  but  not  EBV  Burkitt's  lymphoma  cells,  exclude 
the possibility of an anamnestic recall antigen response be- 
cause CBMC are by definition EBV-. 
What  are  the  possible  advantages  for EBV  expressing  a 
superantigen in infected B  cells? We would predict that the 
superantigen  is  required  for  the  establishment  and/or  the 
maintenance  of persistent  infection.  The EBV latent  genes 
have the  capacity to directly induce B  cell proliferation  in 
vitro  without T  cell help,  rendering superantigen  stimula- 
tion  superfluous.  However,  the  site  of viral  persistence  in 
vivo  is  a  resting  B  cell  that  does  not  express  the  growth- 
promoting  latent  genes  (30).  We  suggest,  therefore,  that 
the role of superantigen-activated T  cells is to provide sig- 
nals necessary for the growth and survival of these latently 
infected  B  cells  in  vivo,  possibly  through  CD40-CD40L 
interaction  (see model in Fig 6).  This would replenish  the 
pool  of latently  infected B  cells,  which  does  not  decrease 
over time,  but remains  remarkably stable  for years  (30).  T 
cell  regulatory  signals  might  also  induce  differentiation  of 
latently infected B  cells,  driving some of them to terminally 
differentiate,  reactivate  the virus,  produce more superanti- 
gen,  and  thereby  complete  the  cycle (Fig.  6).  This  model 
proposes  that  viral  replication  is  essential  for viral  persis- 
tence,  not through reinfection  of B  ceils,  but through su- 
perantigen driven activation of T  ceils. 
A  role  for  T  cells  influencing  EBV  infection  was  sug- 
gested from earlier studies demonstrating that the spontane- 
ous  outgrowth  of LCL  in  vitro  from  EBV-seropositive 
PBMC  is  more  efficient  in  the  presence  of T  cells  (31). 
This  requirement  for  T  cells  is  usually  obscured  by  the 
seemingly converse finding that EBV-specific CTL, which 
arise  later  in  culture,  must  be  depleted  because  they  will 
eliminate  the  newly generated  LCL  (32,  33).  Our  model 
fits  data  obtained  in vivo in  SCID mice transplanted  with 
EBV-seropositive  human  PBMC  (34-36).  These  mice 
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Figure  6.  Role  of the  EBV- 
associated superantigen in infec- 
tion, latency, and disease. After 
EBV infection of resting B cells, 
latent gene expression induces B 
cell  proliferation.  T  cell help 
provides survival signals and sig- 
nals for terminal differentiation. 
This enables lytic cycle viral rep- 
lication and superantigen expres- 
sion in the plasma cells. Activa- 
tion  of V[313 T  cells initiates 
cytokine  production  and  non- 
specific  activation  of  T  cells, 
which  can provide help to  la- 
tently  infected B  cells. Primed 
EBV-specific CTL  will kill  B 
cells  expressing the  full latent 
gene repertoire, selecting for  a 
population of cells that down- 
regulate latent gene expression 
and assume a resting phenotype. 
This  becomes the  site of viral 
persistence throughout  the  life- 
time  of the  host. Periodically, 
these cells can be pushed into vi- 
ral replication by T cell signaling, 
while memory CTL will coun- 
teract the process, maintaining a 
constant EBV burden. 
spontaneously  developed  EBV-associated  B  cell  lympho- 
mas only when T  cells were cotransferred, although the de- 
velopment of EBV-specific CTL limited  tumor formation 
in some of the  mice.  Transplantation  of highly purified B 
cells never yielded lymphomas, even in the presence of cy- 
tokines known to be secreted by activated T  cells  (35), sug- 
gesting that  a  direct  T  cell-B  cell  interaction  is  requisite. 
The tumors that develop are a mixture  of latently infected 
proliferating B  cells,  and terminally  differentiated,  lytically 
infected B  cells that do not divide  (37).  We would predict 
that the nondividing differentiated B cells provide an essen- 
tial growth component for the growing tumor, namely su- 
perantigen-activated  T  cells.  T  cell  signaling  would  pro- 
mote B  cell  survival,  allowing full latent  gene  expression, 
resulting  in perpetual  B  cell proliferation.  Simultaneously, 
T  cells  might push a fraction of cells to terminally differen- 
tiate,  growth arrest,  produce virus, and more superantigen 
(Fig.  6). Eventually, some of the latently infected, rapidly di- 
viding cells would accumulate mutations in cellular oncogenes 
such as  myc,  allowing them to lose the  T  cell dependence 
and  become  transformed.  This  hypothesis  is  in  fact  sup- 
ported  by  the  SCID/hu  mouse  model,  since  the  tumors 
that arise in SCID mice after long periods of time no longer 
contain the fully differentiated, lytically infected cells (37). 
The  other  side  of the  equation,  for healthy  humans,  is 
the cytotoxic T  cell response (38).  Persistent infection with 
EBV can thus be seen as a balance between the superanti- 
gen driven, T  cell-dependent B cell growth, and the elimi- 
nation oflatently infected proliferating B cells by CTL (Fig. 
6).  The clinical symptoms of IM would arise as a result of 
the  disruption  of this  balance.  During IM,  there  is a rapid 
activation of both CD4 + and CD8 + T  cells early after in- 
fection, presumably as a consequence of superantigen stim- 
ulation, mediated by the cytokine production of V[313 + T 
cells.  A  characteristically massive expansion ensues of non- 
specific,  atypically activated,  apoptotic  CD8 +  T  cells  (39, 
40). The nonspecific activation of CD8 cells possibly delays 
the  development  of virus-specific  CTL.  This  could  be  a 
mechanism for EBV to evade  a specific immune  response 
in establishing latency. 
Paradoxically,  EBV infection during childhood leads  to 
seroconversion with limited  or no clinical symptoms. The 
following scenario provides an explanation for this apparent 
incongruity: In adolescents exposed for the first time to this 
pathogen, the mature T  cell pool is poised to mount a rapid 
superantigen response, while the development of virus-spe- 
cific CTL requires priming,  and is therefore  only effective 
after  an  initial  lag period.  CTL priming  might be  further 
delayed by the superantigen-induced  activation of nonspe- 
cific T  cells,  resulting in the symptoms oflM.  Children,  on 
the  other hand,  would predictably  mount a suboptimal  T 
cell  response  to  the  EBV  superantigen,  as  inferred  from 
murine studies, indicating an impaired immune response to 
viral superantigens in immature animals (41). Thus, in chil- 
dren,  the slower and weaker superantigen  response would 
be  balanced  by the  induction  of EBV-specific  CTL,  pre- 
venting  clinical  manifestations.  It  is  unclear  whether  IM 
represents  an atypical immune response because the symp- 
toms of IM are self-limiting and viral latency is established 
in both cases. 
EBV reactivation in AIDS patients and transplant recipi- 
ents  often  leads  to  the  development  of lymphomas  and 
other lymphoproliferative diseases.  Immunosuppression pref- 
erentially  would  affect  the  virus-specific  memory  CTL, 
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turbing the balance in  the  favor of the latter.  The  loss of 
CTL, which control the spread oflatently infected prolifer- 
ating B  cells, would lead to  unregulated growth,  favoring 
tumor development. 
EBV has also been linked to the induction ofautoimmu- 
nity, especially in  Sjogren's syndrome,  which is associated 
with  elevated levels of the virus in patients  (42).  Of note 
are reports describing a significant increase in V[313 T  cells 
in the lesions of patients with this autoimmune  disease, in- 
dicative of the possible action of an EBV-associated super- 
antigen (43-45). 
Recently, it has been suggested that the presence ofa su- 
perantigen in another herpesvirus, CMV,  causes enhanced 
H1V-1 replication in V1312 T  cells, which function as a res- 
ervoir for  HIV-1  in  infected  patients  (46).  It is  plausible 
that EBV nfight play a similar role as CMV in AIDS, par- 
ticularly since EBV infection is ubiquitous, and it has been 
reported that perturbations in the V[313  compartment  oc- 
cur in patients with HIV infection (47).  In addition, a re- 
cent report describes increased HIV-1  replication as a con- 
sequence  of EBV  lymphoma  development in  SCID  mice 
transplanted  with  EBV-seropositive  PBMC  from  HIV-I 
infected patients (48). 
Perhaps more importantly, we predict that some  of the 
anergy and  apoptosis of T  cells occurring in  HIV patients 
might actually be caused by activation-induced cell death, 
resulting as an  indirect consequence  of EBV  superantigen 
stimulation, e.g., the increased cytokine environment.  Fur- 
thermore,  we speculate that  the atypical, apoptotic CD8 + 
T  cells, which  are massively expanded during IM,  consti- 
tute the same T  cell subset that is augmented in HIV infec- 
tion (49, 50).  In both diseases, elimination ofCD4 + T  cells 
occurs, possibly caused in part by the nonspecific cytotoxic 
activity of these  activated CD8 +  T  cells.  It is conceivable 
that these cells arise during HIV infection as a result of su- 
perantigen expression after EBV reactivation by HIV-I Tat 
(51).  In support of our postulate, a correlation was recently 
found between T  cell apoptosis in HIV-l-infected children 
and  an  increased  burden  of EBV  (52).  Thus,  interfering 
with  the  activation  of V1313  T  cells might  have  relevant 
clinical consequences. 
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